{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:27:17Z","timestamp":1771626437035,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1007\/s11906-003-0016-y","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T06:51:24Z","timestamp":1179989484000},"page":"87-92","source":"Crossref","is-referenced-by-count":12,"title":["Does cyclooxygenase-2 affect blood pressure?"],"prefix":"10.1007","volume":"5","author":[{"given":"Hui-Fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl 56","key":"16_CR1","first-page":"25","volume":"26","author":"PE Lipsky","year":"1999","unstructured":"Lipsky PE: Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J Rheumatol 1999, 26(Suppl 56):25\u201330.","journal-title":"J Rheumatol"},{"key":"16_CR2","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1073\/pnas.88.7.2692","volume":"88","author":"WL Xie","year":"1991","unstructured":"Xie WL, Chipman JG, Robertson DL, et al.: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991, 88:2692\u20132696.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/bbrc.1994.2167","volume":"203","author":"R Tazawa","year":"1994","unstructured":"Tazawa R, Xu XM, Wu KK, Wang LH: Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994, 203:190\u2013199.","journal-title":"Biochem Biophys Res Commun"},{"key":"16_CR4","first-page":"F460","volume":"272","author":"M Komhoff","year":"1997","unstructured":"Komhoff M, Grone HJ, Klein T, et al.: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997, 272:F460-F468.","journal-title":"Am J Physiol"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI117620","volume":"94","author":"RC Harris","year":"1994","unstructured":"Harris RC, McKanna JA, Akai Y, et al.: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504\u20132510.","journal-title":"J Clin Invest"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1172\/JCI10318","volume":"106","author":"HF Cheng","year":"2000","unstructured":"Cheng HF, Wang JL, Zhang MZ, et al.: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest 2000, 106:681\u2013688.","journal-title":"J Clin Invest"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0014-5793(99)01088-1","volume":"457","author":"F Nantel","year":"1999","unstructured":"Nantel F, Meadows E, Denis D, et al.: Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999, 457:475\u2013477.","journal-title":"FEBS Lett"},{"key":"16_CR8","doi-asserted-by":"crossref","first-page":"F481","DOI":"10.1152\/ajpcell.1998.274.2.C481","volume":"274","author":"T Yang","year":"1998","unstructured":"Yang T, Singh I, Pham H, et al.: Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998, 274:F481\u2013489.","journal-title":"Am J Physiol"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1172\/JCI5505","volume":"103","author":"HF Cheng","year":"1999","unstructured":"Cheng HF, Wang JL, Zhang MZ, et al.: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999, 103:953\u2013961.","journal-title":"J Clin Invest"},{"key":"16_CR10","first-page":"F706","volume":"277","author":"TR Traynor","year":"1999","unstructured":"Traynor TR, Smart A, Briggs JP, Schnermann J: Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999, 277:F706\u2013710.","journal-title":"Am J Physiol"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1046\/j.1523-1755.2001.00988.x","volume":"60","author":"MC Kammerl","year":"2001","unstructured":"Kammerl MC, Nusing RM, Richthammer W, et al.: Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 2001, 60:1684\u20131691.","journal-title":"Kidney Int"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"F449","DOI":"10.1152\/ajprenal.2001.280.3.F449","volume":"280","author":"HF Cheng","year":"2001","unstructured":"Cheng HF, Wang JL, Zhang MZ, et al.: Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001, 280:F449\u2013456.","journal-title":"Am J Physiol Renal Physiol"},{"key":"16_CR13","doi-asserted-by":"crossref","first-page":"F819","DOI":"10.1152\/ajprenal.2000.279.5.F819","volume":"279","author":"T Yang","year":"2000","unstructured":"Yang T, Endo Y, Huang YG, et al.: Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000, 279:F819\u2013825.","journal-title":"Am J Physiol Renal Physiol"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1046\/j.1523-1755.2001.00072.x","volume":"60","author":"K Athirakul","year":"2001","unstructured":"Athirakul K, Kim HS, Audoly LP, et al.: Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 2001, 60:2324\u20132329.","journal-title":"Kidney Int"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1081\/JDI-100104716","volume":"23","author":"KN Khan","year":"2001","unstructured":"Khan KN, Stanfield KM, Harris RK, Baron DA: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail 2001, 23:321\u2013330.","journal-title":"Renal Fail"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1046\/j.1523-1755.2000.00425.x","volume":"58","author":"M Komhoff","year":"2000","unstructured":"Komhoff M, Jeck ND, Seyberth HW, et al.: Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000, 58:2420\u20132424.","journal-title":"Kidney Int"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0009-9236(01)49789-X","volume":"70","author":"MC Kammerl","year":"2001","unstructured":"Kammerl MC, Nusing RM, Schweda F, et al.: Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin Pharmacol Ther 2001, 70:468\u2013474.","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR18","first-page":"290","volume":"46","author":"DO Stichtenoth","year":"1998","unstructured":"Stichtenoth DO, Wagner B, Frolich JC: Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers. J Investig Med 1998, 46:290\u2013296.","journal-title":"J Investig Med"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1523-1755.2002.00435.x","volume":"62","author":"SC Reinalter","year":"2002","unstructured":"Reinalter SC, Jeck N, Brochhausen C, et al.: Role of cyclooxygenase-2 in hyperprostaglandin E syndrome\/antenatal Bartter syndrome. Kidney Int 2002, 62:253\u2013260.","journal-title":"Kidney Int"},{"key":"16_CR20","doi-asserted-by":"crossref","first-page":"10D","DOI":"10.1016\/S0002-9149(02)02232-4","volume":"89","author":"RC Harris Jr","year":"2002","unstructured":"Harris RC Jr: Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002, 89:10D-17D.","journal-title":"Am J Cardiol"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.2001.281.1.F1","volume":"281","author":"RC Harris","year":"2001","unstructured":"Harris RC, Breyer MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001, 281:F1\u201311.","journal-title":"Am J Physiol Renal Physiol"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/01.HYP.34.5.1163","volume":"34","author":"JM Gross","year":"1999","unstructured":"Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension 1999, 34:1163\u20131167.","journal-title":"Hypertension"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bjp.0704528","volume":"135","author":"M Lopez-Parra","year":"2002","unstructured":"Lopez-Parra M, Claria J, Planaguma A, et al.: Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002, 135:891\u2013900.","journal-title":"Br J Pharmacol"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.HYP.30.3.687","volume":"30","author":"CP Vio","year":"1997","unstructured":"Vio CP, Cespedes C, Gallardo P, Masferrer JL: Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997, 30:687\u2013692.","journal-title":"Hypertension"},{"key":"16_CR25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.36.2.276","volume":"36","author":"F Rodriguez","year":"2000","unstructured":"Rodriguez F, Llinas MT, Gonzalez JD, et al.: Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000, 36:276\u2013281.","journal-title":"Hypertension"},{"key":"16_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002280000161","volume":"56","author":"KB Svendsen","year":"2000","unstructured":"Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 2000, 56:383\u2013388.","journal-title":"Eur J Clin Pharmacol"},{"key":"16_CR27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0009-9236(99)70056-1","volume":"66","author":"J Rossat","year":"1999","unstructured":"Rossat J, Maillard M, Nussberger J, et al.: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66:76\u201384.","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38195-9","volume":"289","author":"F Catella-Lawson","year":"1999","unstructured":"Catella-Lawson F, McAdam B, Morrison BW, et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289:735\u2013741.","journal-title":"J Pharmacol Exp Ther"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinte.160.10.1465","volume":"160","author":"A Whelton","year":"2000","unstructured":"Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465\u20131470.","journal-title":"Arch Intern Med"},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","volume":"96","author":"BF McAdam","year":"1999","unstructured":"McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272\u2013277.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI10228","volume":"107","author":"R Komers","year":"2001","unstructured":"Komers R, Lindsley JN, Oyama TT, et al.: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001, 107:889\u2013898.","journal-title":"J Clin Invest"},{"key":"16_CR32","first-page":"193","volume":"131","author":"T Kistler","year":"2001","unstructured":"Kistler T, Ambuhl PM: Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med Wkly 2001, 131:193\u2013198.","journal-title":"Swiss Med Wkly"},{"key":"16_CR33","first-page":"604","volume":"163","author":"BH Chen","year":"2000","unstructured":"Chen BH: COX-2 inhibitors and renal function in elderly people. Can Med Assoc J 2000, 163:604.","journal-title":"Can Med Assoc J"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-133-1-200007040-00002","volume":"133","author":"SK Swan","year":"2000","unstructured":"Swan SK, Rudy DW, Lasseter KC, et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000, 133:1\u20139.","journal-title":"Ann Intern Med"},{"key":"16_CR35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00002018-200225070-00007","volume":"25","author":"SR Ahmad","year":"2002","unstructured":"Ahmad SR, Kortepeter C, Brinker A, et al.: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002, 25:537\u2013544.","journal-title":"Drug Saf"},{"key":"16_CR36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"AG Johnson","year":"1994","unstructured":"Johnson AG, Nguyen TV, Day RO: Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289\u2013300.","journal-title":"Ann Intern Med"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","volume":"153","author":"JE Pope","year":"1993","unstructured":"Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477\u2013484.","journal-title":"Arch Intern Med"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0009-9236(01)78384-1","volume":"70","author":"RM Nusing","year":"2001","unstructured":"Nusing RM, Reinalter SC, Peters M, et al.: Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome\/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 2001, 70:384\u2013390.","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.HYP.34.1.96","volume":"34","author":"JL Wang","year":"1999","unstructured":"Wang JL, Cheng HF, Harris RC: Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999, 34:96\u2013101.","journal-title":"Hypertension"},{"key":"16_CR40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247\u20131255. The CLASS Study was a double-blind, randomized control trial conducted from September 1998 to March 2000 to compare the effect and safety of celecoxib versus NSAIDs for osteoarthritis and rheumatoid arthritis.","journal-title":"JAMA"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","volume":"21","author":"DC Brater","year":"2001","unstructured":"Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001, 21:1\u201315.","journal-title":"Am J Nephrol"},{"key":"16_CR42","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","volume":"354","author":"P Emery","year":"1999","unstructured":"Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106\u20132111.","journal-title":"Lancet"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520\u20131528. The VIGOR study was a large double-blind, randomized, controlled trial to study the effect and safety of rofecoxib versus NSAIDs in rheumatoid arthritis.","journal-title":"N Engl J Med"},{"key":"16_CR44","unstructured":"FDA Arthritis Advisory Committee Meeting. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/ 3677b2_01_merck.pdf. Accessed December 2001."},{"key":"16_CR45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","volume":"7","author":"A Whelton","year":"2000","unstructured":"Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000, 7:159\u2013175.","journal-title":"Am J Ther"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2296-3-10","volume":"3","author":"E Collantes","year":"2002","unstructured":"Collantes E, Curtis SP, Lee KW, et al.: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002, 3:10.","journal-title":"BMC Fam Pract"},{"key":"16_CR47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.0000014323.99765.16","volume":"39","author":"WB White","year":"2002","unstructured":"White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929\u2013934. This is a very recent randomized, double-blind, placebo-controlled, parallel-group clinical trial to investigate the effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.","journal-title":"Hypertension"},{"issue":"Suppl 3A","key":"16_CR48","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/S0002-9343(00)00699-9","volume":"110","author":"A Whelton","year":"2001","unstructured":"Whelton A: Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001, 110(Suppl 3A):33S-42S.","journal-title":"Am J Med"},{"issue":"Suppl 56","key":"16_CR49","first-page":"18","volume":"26","author":"G Singh","year":"1999","unstructured":"Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26(Suppl 56):18\u201324.","journal-title":"J Rheumatol"},{"key":"16_CR50","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","volume":"106","author":"A Whelton","year":"1999","unstructured":"Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.","journal-title":"Am J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-003-0016-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0016-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T16:03:59Z","timestamp":1737043439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-003-0016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11906-003-0016-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}